Pre‐treatment magnetic resonance enterography findings predict the response to TNF‐alpha inhibitors in Crohn's disease

• DOI: 10.1111/apt.16069
• Publication Date: 2020-09-09T08:01:50Z
• Authors: Jordi Rimola; Agnès Fernàndez‐C...; Nunzia Capozzi; Sònia Rojas‐Farreras; Ignacio Alfaro; Sonia Rodríguez; Maria‐Carme Masamunt; Elena Ricart; Ingrid Ordás; Julian Panés
• Keywords: Clinical endpoint

Identifying predictors of therapeutic response is the cornerstone personalised medicine.To identify long-term healing severe inflammatory lesions based on magnetic resonance enterography (MRE) findings in patients with Crohn's disease (CD) treated tumour necrosis factor alpha (TNF-α) inhibitors.This prospective longitudinal single-centre study included clinically active CD requiring treatment TNF-α inhibitors at least one intestinal segment a lesion detected by MRE (segmental MaRIA ≥11). data were obtained baseline, and weeks 14 46. The primary endpoint was (MaRIA <11) each segment. secondary all per-patient analysis.We 58 86 segments lesions. At week 46, found 51/86 (59.3%) segments, complete 28/58 (48.6%) patients. Multivariable analysis baseline-negative inflammation ileal (as opposed to colonic) location (OR 0.00, [0.00-0.56] P = 0.002) presence creeping fat 0.00 [0.00-0.57]; 0.001). Persistence segmental score >10.6 negative predictor 46 0.3 [0.04--0.38]; < 0.001).In CD, absence baseline are relevant under inhibitors.